利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

2 条记录 (耗时 0.015 秒)

    RNAi-RELATED INHIBITION OF TNF alpha SIGNALING PATHWAY FOR TREATMENT OF GLAUCOMA
    1.
    发明申请
    RNAi-RELATED INHIBITION OF TNF alpha SIGNALING PATHWAY FOR TREATMENT OF GLAUCOMA 审中-公开
    肿瘤坏死因子α信号通路治疗玻璃体的RNAi相关抑制

    公开(公告)号：US20150057336A1

    公开(公告)日：2015-02-26

    申请号：US14484972

    申请日：2014-09-12

    申请人： Alcon Research, Ltd.

    发明人： Jon E. Chatterton ,  Abbot F. Clark ,  David P. Bingaman ,  Martin B. Wax ,  Adrian M. Timmers

    IPC分类号： C12N15/113

    CPC分类号： C12N15/1138 ,  C12N15/1137 ,  C12N2310/111 ,  C12N2310/14 ,  C12N2310/141 ,  C12N2310/53 ,  C12N2310/531

    摘要： RNA interference is provided for inhibition of tumor necrosis factor α (TNFα) by silencing TNFα cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNFα converting enzyme (TACE/ADAM17) mRNA expression. Silencing such TNFα targets, in particular, is useful for treating patients having a TNFα-related condition or at risk of developing a TNFα-related condition such as the ocular conditions associated with elevated intraocular pressure (TOP), including glaucoma and ocular hypertension.

    摘要翻译： 通过沉默TNFα细胞表面受体TNF受体-1（TNFR1）mRNA表达或沉默TNFα转化酶（TACE / ADAM17）mRNA表达，提供RNA干扰抑制肿瘤坏死因子α（TNFα）。 特别是使TNFα靶标沉默可用于治疗患有TNFα相关病症或出现TNFα相关病症风险的患者，如与眼内压升高（TOP）相关的眼部疾病，包括青光眼和高眼压症。